TNFRSF10A and cancer: To investigate if cancer cell sensitivity to TRAIL is linked with DR4 and DR5 expression, all the tested cancer cell lines and a normal HBECs were examined for DR4 and DR5 expression using PE-conjugated antibody surface staining and FACS analysis.